Category: imidazoles-derivatives

Post-transplantation cyclophosphamide uniquely restrains alloreactive CD4+ T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation was written by Hadjis, Ashley D.;Nunes, Natalia S.;Khan, Shanzay M.;Fletcher, Rochelle E.;de Paula Pohl, Alessandra;Venzon, David J.;Eckhaus, Michael A.;Kanakry, Christopher G.. And the article was included in Frontiers in Immunology in 2022.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-vs.-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works by inducing functional impairment and suppression of alloreactive T cells. We also have identified that reduced proliferation of alloreactive CD4+ T cells at day +7 and preferential recovery of CD4+CD25+Foxp3+ regulatory T cells (Tregs) at day +21 are potential biomarkers associated with optimal PTCy dosing and timing in our B6C3F1!B6D2F1 MHC-haploidentical murine HCT model. To understand whether the effects of PTCy are unique and also to understand better the biol. of GVHD prevention by PTCy, here we tested the relative impact of cyclophosphamide compared with five other optimally dosed chemotherapeutics (methotrexate, bendamustine, paclitaxel, vincristine, and cytarabine) that vary in mechanisms of action and drug resistance. Only cyclophosphamide, methotrexate, and cytarabine were effective in preventing fatal GVHD, but cyclophosphamide was superior in ameliorating both clin. and histopathol. GVHD. Flow cytometric analyses of blood and spleens revealed that these three chemotherapeutics were distinct in constraining conventional T-cell numerical recovery and facilitating preferential Treg recovery at day +21. However, cyclophosphamide was unique in consistently reducing proliferation and expression of the activation marker CD25 by alloreactive CD4+Foxp3- conventional T cells at day +7. Furthermore, cyclophosphamide restrained the differentiation of alloreactive CD4+Foxp3- conventional T cells at both days +7 and +21, whereas methotrexate and cytarabine only restrained differentiation at day +7. No chemotherapeutic selectively eliminated alloreactive T cells. These data suggest that constrained alloreactive CD4+Foxp3- conventional T-cell numerical recovery and associated preferential CD4+CD25+Foxp3+ Treg reconstitution at day +21 may be potential biomarkers of effective GVHD prevention. Addnl., these results reveal that PTCy uniquely restrains alloreactive CD4+Foxp3- conventional T-cell proliferation and differentiation, which may explain the superior effects of PTCy in preventing GVHD. Further study is needed to determine whether these findings also hold true in clin. HCT. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis was written by Hadi, I.;Schummer, A.;Dreyling, M.;Eze, C.;Bodensohn, R.;Roengvoraphoj, O.;Belka, C.;Li, M.. And the article was included in Scientific Reports in 2021.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

To analyze the effectiveness and toxicities of radiotherapy in indolent non-Hodgkin’s lymphoma (iNHL) patients treated in our institution. Patients with iNHL treated with radiotherapy between 1999 and 2016 were included. The primary endpoint was progression-free survival (PFS). Secondary endpoints were local control (LC), overall survival (OS) and toxicities. PFS, LC, and OS were analyzed using Kaplan-Meier method. Log-rank test was used to investigate the differences between subgroups. Cox proportional hazard model was used for univariate continuous anal. Seventy-five patients were identified in our institutional database between 1999 and 2016. Fifty-eight (77.3%) had stage I after Ann-Arbor and 17 patients (22.7%) had stage II. The median follow-up was 87 mo (95% CI 72-102 mo). Median single dose per fraction was 2.0 Gy (range 1.5-2 Gy) and median total dose was 30.6 Gy (range 16-45 Gy). Radiotherapy was performed in 2D (n = 10; 13.3%), 3D (n = 63; 84.0%) and VMAT (n = 2; 2.7%) techniques, resp. The median PFS was 14.0 years (95% CI 8.3-19.7 years). The estimated PFS after 5 and 10 years were 73.0% and 65.5% in Kaplan-Meier anal., resp. The 5- and 10-yr LC were 94.9% and 92.3%, resp. The 5- and 10-yr OS were 88.6% and 73.9%. In univariate analyses of PFS, younger patients (≤ 60 years old) had significantly superior PFS to those older than 60 years old (5-yr PFS 81.9% vs. 65.1%, p = 0.021). Dose escalation > 36.0 Gy had no prognostic influence in term of PFS (p = 0.425). Extranodal involvement, stage and histol. had no prognostic impact on PFS. Depending on the site of lymphomas, the most common acute side effects were: dermatitis CTCAE° I-II (8.0%), xerostomia CTC° I (8.0%), cataract CTC° I (12.0%) and dry eyes CTC° I-II (14.6%). No adverse event CTC° III was reported. Most acute side effects recovered at 3 to 6 mo after radiotherapy except for CTC° I cataract and xerostomia. Local Radiotherapy was highly effective for treatment of early stage iNHL with no serious side effects in our cohort. The most acute CTCAE° I-II side effects recovered 3 to 6 mo later. Technique advances seem to have further improved effectiveness and tolerability of radiotherapy. Local ethics committee of Ludwig-Maximilian-University (LMU) Munich approved this retrospective anal. on the May 7th, 2019 (Nr. 19-137). This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Clinicopathological and prognostic value of necroptosis-associated lncRNA model in patients with kidney renal clear cell carcinoma was written by Gu, Jun;He, Zexi;Huang, Yinglong;Luan, Ting;Chen, Zhenjie;Wang, Jiansong;Ding, Mingxia. And the article was included in Disease Markers in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:

Necroptosis, a recently identified type of programmed necrotic cell death, is closely related to the tumorigenesis and development of cancer. However, it remains unclear whether necroptosis-associated long noncoding RNAs (lncRNAs) can be used to predict the prognosis of kidney renal clear cell carcinoma (KIRC). This work was designed to probe the possible prognostic worth of necroptosis-associated lncRNAs along with their impact on the tumor microenvironment (TME) in KIRC. The Cancer Genome Atlas (TCGA) database was used to extract KIRC gene expression and clinicopathol. data. Pearson correlation anal. was used to evaluate necroptosis-associated lncRNAs against 159 known necroptosis-associated genes. To define mol. subtypes, researchers used univariate Cox regression anal. and consensus clustering, as well as clin. significance, TME, and tumor immune cells in each mol. subtype. We develop the necroptosis-associated lncRNA prognostic model using univariate Cox regression anal. and least absolute shrinkage and selection operator (LASSO) regression anal. Patients were divided into high- and low-risk groups according to prognostic model. Moreover, comprehensive analyses, including prognostic value, gene set enrichment anal. (GSEA), immune infiltration, and immune checkpoint gene expression, were performed between the two risk groups. Finally, anticancer drug sensitivity analyses were employed for assessing associations for necroptosis-associated lncRNA expression profile and anticancer drug chemosensitivity. Through univariate anal., sixty-nine necroptosis-associated lncRNAs were found to have a significant relationship with KIRC prognosis. Two mol. clusters were identified, and significant differences were found with respect to clinicopathol. features and prognosis. The segregation of patients into two risk groups was done by the constructed necroptosis-associated lncRNA model. The survival prognosis, clin. features, degree of immune cell infiltration, and expression of immune checkpoint genes of high-risk and low-risk groups were all shown to vary. Our study identified a model of necroptosis-associated lncRNA signature and revealed its prognostic role in KIRC. It is expected to provide a reference for the screening of KIRC prognostic markers and the evaluation of immune response. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study was written by Dhanasiri, Sujith;Hollier-Hann, Georgia;Stothard, Catherine;Dhanda, Devender S.;Davies, Faith E.;Rodriguez-Otero, Paula. And the article was included in Clinical Therapeutics in 2021.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Patients with relapsed and refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options after exposure to an immunomodulatory drug, proteasome inhibitor (PI), and anti-CD38 antibody (triple-class exposure [TCE]). However, current understanding about the management of these patients and associated health care resource use (HCRU) is limited outside the United States. The objective of the International Treatment pattern and resource use Evaluation for Multiple myeloma In a Study of triple-class Exposed patients (ITEMISE) study was to use a physician-developed survey fielded to hematologists across Europe and Canada to assess the treatment, management, HCRU, and end-of-life care for patients with RRMM after TCE.The ITEMISE study used a 3-phase Delphi-like approach that consisted of in-depth interviews with 7 hematol. experts; the development of a cross-sectional survey fielded to hematologists across Belgium, Canada, France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland, and the United Kingdom from August to Oct. 2020; and a final workshop of hematol. experts to validate the pooled findings. Hematologists were asked to consider the management of patients in the first 3 treatment lines after TCE, including treatment options, treatment duration and outcomes, and frequency of outpatient visits and hospitalizations.The survey was completed by 202 hematologists (60% from academic hospitals, 38% from other public hospitals, and 2% from private hospitals). Hematologists estimated that 55% of patients would receive active treatment after TCE, the equivalent of fourth-line treatment onward since diagnosis of multiple myeloma. Immunomodulatory drug, anti-CD38 antibody plus immunomodulatory drug, and PI-based regimens (received by 22.5%, 17.8%, and 15.1% of patients, resp.) were reported for first treatment strategy after TCE. Pomalidomide, daratumumab, lenalidomide, bortezomib, and carfilzomib were the most frequently selected antimyeloma agents. Associated outcomes of median overall survival, progression-free survival, and objective response rate for first treatment after TCE were estimated as 12 mo, 4 mo, and 40%, resp. HCRU included outpatient visits and unplanned hospitalizations that were commonly reported during treatment after TCE. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Eco-efficient and green method for the enhanced dissolution of aromatic crude oil sludge using ionic liquids was written by Sakthivel, Sivabalan;Velusamy, Sugirtha;Gardas, Ramesh L.;Sangwai, Jitendra S.. And the article was included in RSC Advances in 2014.Application of 478935-29-4 The following contents are mentioned in the article:

The upstream petroleum industry faces operational and tech. problems due to increased deposition of waxes, aromatics and asphaltene from crude oil sludge in oil storage tanks in the form of tank-bottom sludge (TBS). This results in huge production losses, and threatens environmentally safe operation; therefore, safer solutions are needed. In this work, nine aromatic ionic liquids (ILs) are synthesized and tested for the dissolution of TBS with the aid of five solvents, namely, toluene, heptane, decane, Et acetate and hexane. The UV absorbance values of the standard solutions (TBS in solvent) are compared with the sample solutions (TBS in solvent + ILs). It is observed that ILs significantly improve the dissolution of TBS in solvents compared with neat solvent alone. Different weight ratios of TBS : ILs (1 : 1, 1 : 0.5 and 1 : 0.1) are considered in this study. Ionic liquids (ILs) based on an imidazolium cation and various anions, such as [Cl]^–, [Br]^–, [BF₄]^–, [H₂PO₄]^–, [HSO₄]^–, and [PF₆]^–, are considered in this investigation. It is observed that the dissolution of TBS in heptane in the presence of [HMIM]⁺[Br]^– is efficient to a maximum extent of 66% with other solvents showing similar increased solubility effect with various ILs. In the case of hexane, it should be noted that the efficiency of dissolution of TBS goes on decreasing with increasing concentration of TBS in hexane. A hold-time study is also performed with heptane containing ILs and heptanes without ILs to determine the maximum time required for efficient dissolution of TBS. It is observed that the efficiency is increased beyond 66% in the presence of ILs for the dissolution of TBS in heptane, provided that the mixture of solvent and ILs are in contact with the TBS for a prolonged period of 30 days, or even longer as required. FT-IR and ¹³C-NMR spectral analyses are also performed so as to understand the efficiency of the ILs in the dissolution of TBS in various solvents, and it was observed that there is a decrease in the intensity of the peaks in the spectra of treated TBS with solvents, which is further enhanced by the addition of ILs. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Application of 478935-29-4).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Application of 478935-29-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole was written by Abed, Mohammed N.;Alassaf, Fawaz A.;Jasim, Mahmood H. M.;Alfahad, Mohanad;Qazzaz, Mohannad E.. And the article was included in Pharmacology in 2020.SDS of cas: 117976-90-6 The following contents are mentioned in the article:

Peptic lesions usually develop when there is an imbalance between aggressive drivers and gastro-protective mediators that guard the lining of the gastrointestinal tract. The most crucial of these mediators are antioxidants, whose loss may predispose to oxidative stress, which is believed to be the main aggravator of several diseases including peptic ulcer. Proton pump inhibitors (PPIs) are drugs that are highly effective and widely used for therapeutic management of peptic disorders through inhibition of gastric acid secretion. In spite of this, oxidative damage may continue to be a major issue that can predispose to future lesions. The present study is designed to explore the possible antioxidant capability of different PPIs, including omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, in an aim to suggest an agent that, in addition to its acid-suppression properties, can provide antioxidant profit. The antioxidant activity of different PPIs was evaluated calorimetrically to test the ability of each drug to quench oxygen free radical, using the well-known stable free radical α,α-diphenyl-β-picrylhydrazyl (DPPH), and compared to ascorbic acid (AA; vitamin C). The measurements were performed using a spectrophotometer at 517 nm. All the studied drugs reduced DPPH, but to different extents. However, omeprazole and esomeprazole showed the highest ability to scavenge free radicals (50% inhibitory concentrations [IC₅₀/s] of the percentage for free radical scavenging activity are 18.7 ± 5.7 and 18.7 ± 5.7, resp., and the AA equivalent are 83,772 ± 11,887 and 81,732 ± 8,523 mg AA/100 g, resp.). Conversely, lansoprazole, pantoprazole, and rabeprazole might be having no role in this story (IC₅₀/s of the percentage for free radical scavenging activity are 49.3 ± 3.1, 49 ± 9.4, and 40.7 ± 7.2, resp., and the AA equivalent are 30,458 ± 3,884, 32,222 ± 10,377, and 37,876 ± 8,816 mg AA/100 g, resp.). Thus, omeprazole and esomeprazole may confer a significant dual action in gastrointestinal protection by providing potent antioxidant properties in addition to their major role as acid-suppression agents. However, further studies are essential to elucidate the mechanism behind the difference between the drugs of the same class. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6SDS of cas: 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.SDS of cas: 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax was written by Gango, Ambrus;Kiss, Richard;Farkas, Peter;Hanna, Eid;Demeter, Judit;Deak, Beata;Levai, Dora;Kotmayer, Lili;Alpar, Donat;Matolcsy, Andras;Bodor, Csaba;Matrai, Zoltan;Timar, Botond. And the article was included in Pathology in 2022.Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Richter syndrome (RS) represents the development of high-grade lymphoma in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and presents a diagnostic and therapeutic challenge with an adverse prognosis. The genetic background and morphol. of RS in CLL patients treated with chemoimmunotherapy is extensively characterised; however, our knowledge about RS in patients treated with targeted oral therapies should be extended. To understand the morphol. and mol. changes leading to RS in CLL patients treated with the Bruton’s tyrosine kinase inhibitor, ibrutinib, and the BCL2 inhibitor, venetoclax, sequential samples from six CLL/SLL patients undergoing RS were collected in both the CLL and RS phases. A detailed immunophenotypic anal. of formalin-fixed, paraffin-embedded tissue specimens of RS phase was performed, followed by extensive mol. characterization of CLL and RS samples, including the Ig heavy chain gene (IGH) rearrangement, TP53 mutations, drug-induced resistance mutations in BTK and BCL2 genes and various copy number changes and point mutations detectable with multiplex ligation-dependent probe amplification (MLPA). Rare, non-diffuse large B-cell lymphoma phenotypes of RS were observed in 3/6 cases, including plasmablastic lymphoma and a transitory entity between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. The majority of cases were clonally related and harboured an unmutated variable region of the Ig heavy chain gene. Abnormalities affecting the TP53 gene occurred in all patients, and every patient carried at least one genetic abnormality conferring susceptibility to RS. In the background of RS, 2/5 patients treated with ibrutinib showed a BTK C481S resistance mutation. One patient developed a BCL2 G101V mutation leading to venetoclax resistance and RS. In conclusion, our findings contribute to better understanding of RS pathogenesis in the era of targeted oral therapies. Rare phenotypic variants of RS do occur under the treatment of ibrutinib or venetoclax, and genetic factors leading to RS are similar to those identified in patients treated with chemoimmunotherapy. To our best knowledge, we have reported the first BCL2 G101V mutation in an RS patient treated with venetoclax. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Highly selective, sensitive and stable three-dimensional luminescent metal-organic framework for detecting and removing of the antibiotic in aqueous solution was written by Wu, Ruixue;Bi, Caifeng;Zhang, Dongmei;Fan, Chuanbin;Wang, Lulu;Zhu, Bin;Liu, Wenbo;Li, Nana;Zhang, Xia;Fan, Yuhua. And the article was included in Microchemical Journal in 2020.Name: 3,5-Di(1H-imidazol-1-yl)pyridine The following contents are mentioned in the article:

An efficiently selective sensor for aquatic antibiotic detection based on a photoluminescent cadmium metal-organic framework (Cd-MOF) is researched in this work. The novel and simple luminescent MOF that composed from aπ-electron rich ligand bip (3,5-bis(1-imidazol) pyridine) and H₃L (2-nitro-5-(4-carboxy-2-nitrophenoxy) isophthalic) was synthesized in hydrothermal condition and characterized. Single crystal X-ray diffraction anal. demonstrated that it had an uncommon 2-nodal (3,6)-connected 3D framework with a (3²·4)(3⁴·4⁶·5³·6²) topol., which could be formulated as [{[Cd₂(HL)₂(bip)₂]·H₂O}_n]. Benefiting from its unique framework, [{[Cd₂(HL)₂(bip)₂]·H₂O}_n] can not only respond to the trace quantity of chloramphenicol (CHL) via fluorescence quenching but also show good adsorption capability toward CHL in aqueous solution The selective response to CHL reached up to the ppb level with high anti-interference ability in aqueous phase, and the effective detection of antibiotics had been theorized by D. Functional Theory (DFT) calculation for energy bands of H₃L and antibiotics, which revealed that the cooperation influence on photo-induced electron transfer (PET) process and fluorescence inner filter effect (IFE) made CHL show more sensitive luminescence responses than other exptl. antibiotics. Moreover, because of its specific interactions with analytes and relatively high porosity, the pre-enrichment makes the antibiotic fuller contact and interact with the framework, which improves the overall sensing efficiency toward CHL appreciably. Stemming from the abuse, antibiotics have been considered as the great threat to the health of human race and the sustainable development of society. Therefore, it is extremely important to achieve new technol. to detect and absorb antibiotics residues in water. This work proves that metal-organic framework complexes can conform the performance of detecting and removing antibiotic in aqueous environment, that emphasizes the application of luminescent MOFs in contaminant monitoring and removing. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Name: 3,5-Di(1H-imidazol-1-yl)pyridine).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Name: 3,5-Di(1H-imidazol-1-yl)pyridine

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors was written by Shen, Tianxiang;Jiang, Xindong;Jin, Zhaolei;Ji, Qiuzhi;Li, Chunlong;Li, Qingpo;Long, Hongxin;Qiu, Weigen;Wang, Wei;Hou, Xuemei;You, Jian. And the article was included in European Journal of Pharmaceutics and Biopharmaceutics in 2020.Electric Literature of C18H20N3NaO3S The following contents are mentioned in the article:

The major therapeutic strategy for acid-related gastrointestinal diseases in clinic is to reduce the excretion of gastric acid by oral administration of proton-pump inhibitors (PPIs). However, it is quite a challenge to study the oral absorption behaviors of PPIs considering their extreme instability under gastrointestinal environment. As a result, little information has been reported on PPI oral absorption so far, hindering the further development of PPI-contained oral preparations Here, we first investigated the degradation rate of three representative PPIs, including ilaprazole, ilaprazole sodium and rabeprazole sodium. Then a modified in situ intestine absorption method in rat was established: through the temperature control by the heat exchangers, the perfusate was kept at physiol. temperature only when passing through the intestine while it was maintained at 4°C outside the intestine. Therefore PPIs could maintained sufficiently high stability under proper temperature control. Our data demonstrated that both ilaprazole and ilaprazole sodium exhibited significantly higher absorption efficiency than rabeprazole sodium did through the comparison of their apparent permeability coefficients and steady-state plasma concentrations after perfusion in the duodenum, jejunum, ileum and colon, mainly attributing to their more suitable oil-water partition coefficient The duodenum could be the best site for the oral absorption of PPIs. Ilaprazole outperformed its sodium salt form with its stable absorption behavior in tested four intestinal segments. Furthermore, after i.v. or oral administration, ilaprazole exhibited a longer residence time and a higher accumulation in the stomach than in most of other tissues/organs. However, it was also found that the accumulation was heterogeneous and mainly located in mucosa cells of the stomach. Our further study indicated that there was no significant difference on the oral absorption efficiency of ilaprazole between female and male rats but ilaprazole underwent a faster metabolism in male rats after oral absorption. Our study provided a valuable guidance for the design of oral formulation and the optimization of PPI-contained formulations. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Electric Literature of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Electric Literature of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Isopolymolybdate-Based Cobalt/Nickel Coordination Polymers Constructed by V-Type N-Donor Ligands was written by Shi, Ya-Jie;Chen, Lin-Lin;Liu, Ying;Wu, Ying-Ying;Li, Ya-Min;Dang, Dong-Bin;Bai, Yan. And the article was included in Inorganic Chemistry in 2021.Formula: C11H9N5 The following contents are mentioned in the article:

Four novel isopolymolybdate-based coordination polymers (CPs), constructed from 2,6-bis(1,2,4-triazol-1-yl)pyridine (btp), 1,3-bis(4H-1,2,4-triazol-4-yl)benzene (btb), and 3,5-bis(1-imidazolium)pyridine (bip), have been synthesized under a hydrothermal method: {[Co(btp)(H₂O)₂(β-Mo₈O₂₆)_0.5]·3H₂O}_n (1), [Ni(btp)(H₄Mo₆O₂₂)_0.5]_n (2), [Co(btb)(H₂O)(β-Mo₈O₂₆)_0.5]_n (3), and {[Co(Hbip)₂(H₂O)₂(γ-Mo₈O₂₆)]·6H₂O}_n (4). Complex 1 exhibits one 3D framework with an unexpected 3-nodal 2,4,6-c net topol. containing the 1D {β-Mo₈O₂₆}_n chains, 6-connected Co^II centers, and V-type coordinated btp ligands. The neighboring [Mo₆O₂₂]^4- anions of complex 2 are bridged by the Ni^II centers to build one 2D {Ni₂(Mo₆O₂₂)} network, which is arranged into the 3D framework through the weak π···π stacking interactions. In compound 3, one 3D framework is formed by the adjacent 1D {Co₂(btp)₂}_n chains connected by {β-Mo₈O₂₆}_n units, which demonstrates a rare 4,6-c fsc topol. In complex 4, one 2D {Co(Hbip)₂(γ-Mo₈O₂₆)} layer with a (4, 4) network is connected to one 3D hydrogen-bonding framework via N-H···O and O-H···O hydrogen bonds. Magnetic data indicate that complexes 1 and 4 exhibit antiferromagnetic behaviors, whereas complexes 2 and 3 reveal spin-canting magnetic behavior and metamagnetic behavior, resp. In addition, the proton conductivity of complexes 3 and 4 was investigated, showing that compound 4 has good proton conductivity at 85° and a relative humidity of 98% RH. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Formula: C11H9N5).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Formula: C11H9N5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem